Endoscopic lung volume reduction

• Verfasst von: Herth, Felix [VerfasserIn]
• Verfasst von: Slebos, Dirk-Jan [VerfasserIn]
• Verfasst von: Criner, Gerard J. [VerfasserIn]
• Verfasst von: Valipour, Arschang [VerfasserIn]
• Verfasst von: Sciurba, Frank [VerfasserIn]
• Verfasst von: Shah, Pallav [VerfasserIn]
• Titel: Endoscopic lung volume reduction
• Titelzusatz: an expert panel recommendation - update 2019
• Verf.angabe: Felix J.F. Herth, Dirk-Jan Slebos, Gerard J. Criner, Arschang Valipour, Frank Sciurba, Pallav L. Shah
• E-Jahr: 2019
• Jahr: June 2019
• Umfang: 10 S.
• Fussnoten: Gesehen am 21.11.2019
• Titel Quelle: Enthalten in: Respiration
• Ort Quelle: Basel : Karger, 1968
• Jahr Quelle: 2019
• Band/Heft Quelle: 97(2019), 6, Seite 548-557
• ISSN Quelle: 1423-0356
• DOI: doi:10.1159/000496122
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1682407411

Abstract

Endoscopic lung volume reduction (ELVR) therapies are gaining prominence as a treatment option with guideline recommendations by COPD GOLD and NICE and the recent FDA approval for endobronchial valves. The transition from an experiment-based therapy only to clinical care comes with new challenges. A significant volume of evidence-based data has been published; all data demonstrate consistent improvements in several aspects of patient outcomes. Patients suffering from severe air trapping and thoracic hyperinflation seem to benefit the most from ELVR. In addition to lung function, baseline assessment should ideally include cardiopulmonary exercise testing, high-resolution computer tomography scan, perfusion scintigraphy, and echocardiography. This expert ELVR statement updates best practice recommendations from 2017 regarding patient selection and utilization of these various techniques for treating patients with advanced emphysema.